6FK Stock Overview
Researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gentian Diagnostics ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 4.90 |
| 52 Week High | NOK 5.05 |
| 52 Week Low | NOK 2.99 |
| Beta | 0.58 |
| 11 Month Change | 25.00% |
| 3 Month Change | 53.13% |
| 1 Year Change | 35.36% |
| 33 Year Change | -15.22% |
| 5 Year Change | n/a |
| Change since IPO | 3.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6FK | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 26.3% | -0.5% | 0.9% |
| 1Y | 35.4% | 2.3% | 5.7% |
Return vs Industry: 6FK exceeded the German Medical Equipment industry which returned 2.3% over the past year.
Return vs Market: 6FK exceeded the German Market which returned 5.7% over the past year.
Price Volatility
| 6FK volatility | |
|---|---|
| 6FK Average Weekly Movement | 10.1% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6FK's share price has been volatile over the past 3 months.
Volatility Over Time: 6FK's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 58 | Njaal Kind | www.gentian.com |
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit.
Gentian Diagnostics ASA Fundamentals Summary
| 6FK fundamental statistics | |
|---|---|
| Market cap | €75.57m |
| Earnings (TTM) | -€510.40k |
| Revenue (TTM) | €13.07m |
5.8x
P/S Ratio-148.1x
P/E RatioIs 6FK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6FK income statement (TTM) | |
|---|---|
| Revenue | NOK 149.41m |
| Cost of Revenue | NOK 68.88m |
| Gross Profit | NOK 80.53m |
| Other Expenses | NOK 86.37m |
| Earnings | -NOK 5.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 53.90% |
| Net Profit Margin | -3.90% |
| Debt/Equity Ratio | 0% |
How did 6FK perform over the long term?
See historical performance and comparison